Can OncoHost's PROphet predict host response to cancer treatments? Investors are waiting to find out
Last year, a small biotech out of Israel scored a modest $8 million in a Series B to help finance clinical trials and prepare for the upcoming launch of its main product, a machine learning-based diagnostics platform. Recently, the biotech went back for more — and got it.
OncoHost announced Tuesday morning that it successfully raised $35 million in a Series C financing round led by Israeli healthtech VC ALIVE, with additional investors including the Series B lead investor, OurCrowd. As to the company’s first goal, it is focusing on the commercial launch of its platform named PROphet, which CEO Ofer Sharon told Endpoints News is slated to launch sometime in Q3 this year — firstly in the US.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters